查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014791

流感診斷市場：依檢測類型/產品類型、檢體類型、技術、檢測方法/實施環境、最終用戶和疾病分類－2026-2032年全球市場預測

Influenza Diagnostics Market by Test Type / Product Type, Sample Type, Technology, Mode of Testing / Setting, End User, Disease Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，流感診斷市值將達到 14.3 億美元，到 2026 年將成長到 15.6 億美元，到 2032 年將達到 28.6 億美元，複合年成長率為 10.38%。

主要市場統計數據
基準年 2025 14.3億美元
預計年份：2026年 15.6億美元
預測年份 2032 28.6億美元
複合年成長率 (%) 10.38%

從策略觀點正在重塑所有醫療保健機構流感診斷的臨床、技術和營運因素的變化。

流感診斷領域正經歷快速發展，其驅動力包括不斷成長的疫情防範需求、技術的成熟以及臨床工作流程的系統性變革。診斷需求已不再局限於季節性、間歇性檢測，而是擴展到多參數呼吸道病原體檢測、疫情爆發期間的即時篩檢（POC​​）以及對易感人群的治療後監測。同時，透過檢查室整合和向分散式檢查的轉變，診斷服務的提供和利用方式也在重組。

技術創新、監管進步和營運韌性正在重新定義流感診斷的提供地點、方式和提供者。

近年來，流感診斷領域發生了變革性變化，其特點是分子檢測方法的加速應用、即時檢測（POC​​）解決方案需求的成長以及集中式和分散式檢查模式的重新平衡。等溫擴增和整合式試劑盒平台的創新為傳統的PCR工作流程提供了一種可靠的替代方案，在許多應用情境中，能夠在不降低分析靈敏度的前提下實現快速的患者現場診斷。同時，多重技術的改進使得同時檢測多種呼吸道病原體成為可能，從而拓展了臨床效用，並為更明智的臨床決策提供了支持。

評估關稅引發的貿易變化對診斷價值鏈中的供應鏈、籌資策略和採購偏好的多方面影響。

關稅和貿易措施的實施會對整個診斷生態系統產生連鎖反應，影響組件成本、供應鏈設計和商業策略。關稅帶來的成本壓力可能會增加進口試劑、耗材和儀器組件的到貨成本。這可能促使製造商重新評估其全球籌資策略，轉移易受影響的生產流程，或協商長期供應合約。為此，一些公司正在加快認證替代材料，以在保持性能的同時降低貿易中斷帶來的風險，並實現供應商多元化。

詳細的細分分析揭示了技術模式和最終用戶管道如何決定產品規格、部署趨勢和商業性方法。

流感診斷的細分涵蓋了不同的技術模式和終端使用者管道，每種模式和管道都有其獨特的效能預期和操作限制。在技​​術路徑方面，分子診斷包括傳統的聚合酵素鏈鎖反應(PCR) 方法、等溫擴增技術和即時PCR平台。雖然傳統的 PCR 仍被優先考慮處理能力和全面檢驗的參考檢查室所採用，但等溫擴增技術，包括恒溫環型核酸擴增和核酸序列擴增等技術，因其簡便性和適用於分散式檢查而日益受到青睞。即時PCR可配置為多重和單重模式，仍是高靈敏度應用和確診流程的核心。快速診斷包括整合檢體處理和檢測的盒式平台（供患者使用）以及提供快速低成本篩檢方法的橫向流動化驗。血清學診斷包括酵素免疫分析法（ELISA）、血凝抑制試驗和中和試驗，這些對於評估免疫狀態、評估疫苗和流行病學監測至關重要。

區域醫療保健基礎設施、法規環境和製造地如何影響診斷方法部署的模式和策略重點？

流感診斷的區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區醫療基礎設施、管理體制和供應鏈結構的差異。在美洲，完善的檢查室網路和健全的報銷機制推動了對高效能分子診斷和整合檢查室解決方案的需求，而區域創新浪潮則加速了即時檢測在當地社區的普及。在歐洲和中東及非洲，由於監管協調的努力以及醫療系統能力的差異，出現了各種不同的情況。集中式實驗室與對分散式檢查（尤其是在偏遠和資源匱乏地區）的日益成長的投資並存。在該地區，採購慣例和公共衛生監測重點影響著產品的選擇和分銷模式。

平台整合、策略夥伴關係和在地化生產所驅動的競爭動態正在決定差異化和長期採購關係。

流感診斷領域的競爭格局呈現出多元化的特點，既有成熟的診斷試劑生產商，也有專注於分子診斷的創新企業，還有不斷發展的試劑盒和照護現場檢測平台開發商。大型企業持續投資於平台整合、拓展檢測參數和建立全球分銷網路，並利用其規模優勢來支援服務模式、品質保證和監管申報。同時，敏捷的科技公司正致力於等溫檢測方法、晶片實驗室整合以及快速抗原檢測技術的改進，並經常與臨床檢查室和檢驗機構合作，以驗證新的應用。

可操作的優先舉措，旨在幫助相關人員加強供應鏈韌性，使產品設計與臨床工作流程保持一致，並透過策略夥伴關係加速部署。

產業領導企業可以採取積極措施來增強韌性、加速產品部署並創造臨床價值。首先，他們可以透過開發與高優先級臨床工作流程相契合的產品，確保產品性能轉化為臨床醫生的實際獲益，例如門診快速排除診斷和用於住院管理的多參數實驗室檢測組合。其次，透過實現價值鏈多元化並投資區域製造能力，可以降低貿易中斷帶來的風險，並有助於在需求高峰期縮短交付時間。第三，透過與實驗室網路、醫療系統和學術機構建立策略合作夥伴關係，可以加速實際應用檢驗，並增強大規模採購商的信心。

我們以證據為基礎的調查方法，結合對關鍵相關人員的訪談、對監管和技術文件的審查以及跨多個資訊來源的三角檢驗，確保了嚴謹且可操作的見解。

本研究結合了臨床實驗室經理、採購經理和產品開發主管的訪談，以及對監管指南、同行評審文獻和儀器及檢測供應商提供的檢驗技術規範的二次分析。此調查方法強調跨資料來源的三角驗證，以確保研究結果的穩健性。質性見解為技術採納提供了依據，而技術文件則為效能特徵評估和互通性研究提供了基礎。

結論強調，技術創新、營運韌性和策略協調的交會是診斷領域持續成功的先決條件。

不斷變化的流感診斷模式既充滿挑戰又蘊藏機會。分子診斷和快速檢測技術的進步，以及醫療保健分散化和供應鏈監管力度加大，正在重新定義臨床客戶的價值來源。同時，地緣政治和貿易發展凸顯了靈活採購和區域製造策略的必要性。對於產業相關人員，成功的關鍵在於將技術創新與卓越營運相結合，滿足跨司法管轄區的監管要求，並透過真實世界的檢驗展現切實的臨床影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：流感診斷市場：依檢測類型/產品類型分類

  • 快速流感診斷測試（RIDT）
  • 基於RT-PCR方法的檢測
  • 恒溫核酸增幅試驗（NAAT）
  • 螢光（IFA）
  • 血清學檢測（ELISA、抗體檢測）
  • 數位/連網診斷設備
  • 多重呼吸道疾病檢測（甲型/乙型流感+呼吸道合胞病毒+新冠病毒）
  • 螢光（IFA）
  • 數位/連網診斷設備
  • 多參數呼吸道疾病檢測（甲型/乙型流感病毒+呼吸道合胞病毒+新冠病毒）
  • 家用/非處方（OTC）流感檢測套組
  • 血清學檢測

第9章：流感診斷市場：檢體類型

  • 鼻咽拭子
  • 咽拭子
  • 支氣管肺泡灌洗液（BAL）
  • 口腔和咽拭子
  • 血液/血清檢體
  • 鼻拭子

第10章：流感診斷市場：依技術分類

  • 分子診斷
    • 常規PCR
    • 等溫擴增
    • 即時PCR
      • 多重PCR試劑盒
      • 單重PCR試劑盒
  • 免疫診斷
    • 橫向流動化驗
    • 化學冷光
    • 螢光
    • ELISA

第11章：流感診斷市場：依檢測方法/實施環境分類

  • 即時檢測（POC​​T）
  • 臨床試驗
  • 家庭測試

第12章：流感診斷市場：依最終用戶分類

  • 學術和研究機構
  • 診所
  • 診斷檢查室
  • 醫院

第13章：流感診斷市場：依疾病分類

  • 季節性流感檢測
  • 旅客篩檢/職業篩檢
  • 疫情大流行/新感染病例檢測
  • 監測與流行病學

第14章：流感診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：流感診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 流感診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國流感診斷市場

第18章：中國流感診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Danaher Company
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics, Inc.
  • Hologic, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • PerkinElmer, Inc.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market was valued at USD 1.43 billion in 2025 and is projected to grow to USD 1.56 billion in 2026, with a CAGR of 10.38%, reaching USD 2.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.43 billion
Estimated Year [2026] USD 1.56 billion
Forecast Year [2032] USD 2.86 billion
CAGR (%) 10.38%

A strategic orientation to the changing clinical, technological, and operational drivers reshaping influenza diagnostics across healthcare delivery settings

The landscape of influenza diagnostics is undergoing a period of accelerated evolution driven by heightened preparedness demands, technological maturation, and system-level shifts in clinical workflows. Diagnostic needs have expanded beyond episodic seasonal testing to encompass multiplexed respiratory panels, point-of-care screening during surge events, and post-therapeutic monitoring for vulnerable populations. Concurrently, laboratory consolidation and the push for decentralized testing have reshaped how diagnostic services are delivered and consumed.

Clinical stakeholders increasingly prioritize speed, analytical performance, and operational simplicity, while health systems emphasize throughput, supply resilience, and cost-effectiveness. These intersecting priorities create a strategic imperative for diagnostics developers and distributors to align product design with real-world use cases across hospital laboratories, outpatient clinics, academic centers, and high-volume diagnostic laboratories. Moreover, regulatory clarity and reimbursement pathways remain decisive factors for adoption, necessitating proactive alignment between product development timelines and policy expectations.

In this context, the report synthesizes clinical drivers, technology readiness, supply chain considerations, and stakeholder incentives into a cohesive view that informs near-term commercial strategy and longer-term investment decisions. The intent is to provide an actionable framework that supports clinical leaders, R&D teams, and commercial strategists as they navigate the complex matrix of clinical need, performance trade-offs, and operational constraints.

How technological innovation, regulatory evolution, and operational resilience are collectively redefining where, how, and by whom influenza diagnostics are delivered

Recent years have seen transformative shifts in the influenza diagnostics landscape characterized by accelerated adoption of molecular testing modalities, greater demand for point-of-care solutions, and a rebalancing of centralized versus decentralized testing models. Innovations in isothermal amplification and integrated cartridge platforms have delivered robust alternatives to traditional PCR workflows, enabling rapid, near-patient diagnostics without compromising analytical sensitivity in many use cases. At the same time, improvements in assay multiplexing have expanded clinical utility by enabling simultaneous detection of multiple respiratory pathogens, which supports more informed clinical decision-making.

Parallel to these technological advances, operational shifts have emerged. Health systems have invested in flexible testing capacity to respond to seasonal surges and unexpected outbreaks, while laboratories have prioritized workflow automation and digital integration to improve throughput and data connectivity. Supply chain resiliency has become a top-tier imperative, prompting suppliers and purchasers to diversify sourcing strategies and to pursue regional manufacturing wherever feasible. Additionally, regulatory agencies globally have refined pathways for emergency use and accelerated approvals, creating windows of opportunity for innovative diagnostics that can demonstrate clinical value and operational fit.

Taken together, these shifts are not merely incremental; they change where testing occurs, who performs it, and how outcomes influence patient pathways. Strategic actors must therefore anticipate the confluence of technology maturation, regulatory evolution, and purchaser expectations to remain competitive and clinically relevant.

Assessing the multifaceted consequences of tariff-driven trade changes on supply chains, sourcing strategies, and procurement preferences within the diagnostics value chain

The introduction of tariffs and trade measures can have cascading effects across the diagnostics ecosystem, influencing component costs, supply chain design, and commercial strategy. Tariff-related cost pressures can raise the landed cost of imported reagents, disposables, and instrument components, thereby incentivizing manufacturers to reassess global sourcing strategies, relocate sensitive production steps, or negotiate longer-term supply contracts. In response, some firms accelerate efforts to diversify suppliers and to qualify alternative materials that preserve performance while mitigating exposure to trade disruptions.

In addition to direct cost implications, tariffs can influence competitive dynamics by altering the relative attractiveness of domestically manufactured versus imported products. For diagnostic companies with global footprints, tariff regimes can prompt restructuring of distribution footprints and pricing strategies to maintain market access while protecting margins. Health systems and laboratories, facing procurement constraints, may place higher value on supply resilience and vendor risk management, which influences procurement contracting and preferred supplier lists.

Regulatory and procurement environments also adapt. Policymakers may complement tariff actions with incentives for local manufacturing capacity, expedited regulatory reviews for domestically produced diagnostics, or strategic stockpiling initiatives. As a result, firms that can demonstrate local production capabilities, robust supply chains, and regulatory compliance gain a strategic advantage. Ultimately, navigating the tariff environment requires integrated cross-functional planning that aligns sourcing, manufacturing, regulatory, and commercial teams to sustain product availability and protect clinical continuity.

Detailed segmentation analysis illuminating how technology modalities and end-user channels dictate product specifications, adoption dynamics, and commercial approaches

Segmentation in influenza diagnostics spans technology modalities and end-user channels, each with distinct performance expectations and operational constraints. Within technology pathways, molecular diagnostics include conventional polymerase chain reaction approaches, isothermal amplification techniques, and real-time PCR platforms. Conventional PCR continues to serve reference laboratories where throughput and comprehensive validation are priorities, while isothermal amplification-comprising methods such as loop-mediated isothermal amplification and nucleic acid sequence-based amplification-has gained traction for its simplicity and suitability for decentralized testing. Real-time PCR, with configurations that support both multiplexing and singleplex formats, remains central to high-sensitivity applications and confirmatory workflows. Rapid diagnostics encompass cartridge-based platforms that integrate sample processing and detection for near-patient use, as well as lateral flow assays that provide quick, low-cost screening options. Serological diagnostics cover enzyme-linked immunosorbent assays, hemagglutination inhibition assays, and neutralization tests, which are critical for immune status assessment, vaccine evaluation, and epidemiologic surveillance.

From an end-user perspective, academic and research institutes seek flexible platforms that support method development and complex panels, while clinics require compact, easy-to-use solutions that deliver rapid actionable results. Diagnostic laboratories prioritize throughput, automation, and data interoperability, and hospitals demand scalable solutions that integrate with laboratory information systems and support inpatient care pathways. The interplay between technology choice and end-user requirements drives product specification, commercial packaging, and support models. For example, multiplex real-time PCR solutions are well aligned to reference laboratories and large hospitals where analytical depth and throughput are essential, whereas isothermal and cartridge-based systems better serve outpatient clinics and decentralized testing sites. Recognizing these alignments enables suppliers to tailor go-to-market strategies, prioritize regulatory submissions, and design service offerings that match operational realities across the clinical landscape.

How regional healthcare infrastructures, regulatory environments, and manufacturing footprints shape divergent adoption patterns and strategic priorities for diagnostics

Regional dynamics in influenza diagnostics reflect differences in healthcare infrastructure, regulatory regimes, and supply chain architectures across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, established laboratory networks and strong reimbursement frameworks drive demand for high-performance molecular assays and integrated laboratory solutions, while pockets of innovation have accelerated the adoption of point-of-care testing in community settings. Across Europe, the Middle East and Africa, regulatory harmonization efforts and variable health system capacities create a heterogeneous landscape in which centralized laboratories coexist with growing investments in decentralized testing to improve access, particularly in remote or resource-constrained areas. Procurement practices and public health surveillance priorities influence product selection and distribution models in this region.

In the Asia-Pacific, a combination of manufacturing capacity, government-led testing initiatives, and rapid uptake of novel platforms has positioned the region as both a major consumer and an important production hub for diagnostic components and assays. Local manufacturers have expanded capabilities across molecular and rapid diagnostics, supporting regional supply chain resilience and enabling tailored solutions for high-volume testing environments. These regional distinctions have implications for regulatory strategy, distribution partnerships, and localization of clinical validation efforts. Consequently, firms seeking regional scale must adapt regulatory submissions, local support models, and supply logistics to the distinct expectations and infrastructure realities of each geography.

Competitive dynamics driven by platform integration, strategic partnerships, and localized production that determine differentiation and long-term procurement relationships

The competitive field in influenza diagnostics is characterized by a mix of established diagnostics manufacturers, specialized molecular innovators, and an expanding set of cartridge and point-of-care platform developers. Large industry players continue to invest in platform integration, expanded assay menus, and global distribution networks, leveraging scale to support service models, quality assurance, and regulatory submissions. At the same time, agile technology companies drive innovation in isothermal methods, lab-on-a-chip integration, and rapid antigen detection enhancements, often partnering with clinical laboratories and research institutions to validate new applications.

Strategic partnerships between instrument providers and assay developers are increasingly important, enabling faster time-to-clinic for novel tests and creating ecosystems that link hardware, consumables, and digital services. In parallel, contract manufacturers and localized production sites have become key components of supply assurance strategies, particularly when trade measures or logistics disruptions constrain cross-border flows. Companies that demonstrate a combination of robust data package quality, responsive technical support, and flexible commercial models will be better positioned to win multi-year procurement agreements with health systems and large laboratory networks. Observing these dynamics, industry participants must balance product innovation with the operational rigor required by clinical customers.

Actionable priority initiatives for stakeholders to fortify supply resilience, align product design with clinical workflows, and accelerate adoption through strategic partnerships

Industry leaders can take proactive steps to strengthen resilience, accelerate adoption, and capture clinical value. First, aligning product development with prioritized clinical workflows-such as rapid rule-out in outpatient settings and multiplexed panels for inpatient management-ensures that performance features translate into actionable benefits for clinicians. Second, investing in supply chain diversification and regional manufacturing capacity reduces exposure to trade disruptions and supports faster delivery times during demand surges. Third, pursuing strategic alliances with laboratory networks, health systems, and academic centers accelerates real-world validation and builds credibility with large purchasers.

In addition, companies should prioritize regulatory strategy as a competitive asset, coordinating evidence generation to support approval pathways across target regions and anticipating changes in regulatory expectations. Commercially, flexible pricing and service models that reflect payer constraints and procurement cycles can unlock broader adoption, especially in decentralized settings. Finally, embedding digital connectivity and data analytics into product offerings enhances customer value by enabling quality control, remote troubleshooting, and integration with electronic health records. By executing on these imperatives, leaders can convert technical advantage into durable clinical and commercial outcomes.

An evidence-driven methodology combining primary stakeholder interviews, regulatory and technical documentation review, and cross-source triangulation to ensure rigorous and actionable findings

This research synthesizes primary interviews with clinical laboratory directors, procurement leads, and product development executives, combined with secondary analysis of regulatory guidance, peer-reviewed literature, and validated technical specifications from instrument and assay providers. The methodological approach emphasizes triangulation across data sources to ensure robustness: qualitative insights inform technology adoption narratives, while technical documentation underpins performance characterizations and interoperability considerations.

Field engagement included structured conversations to surface operational constraints, procurement criteria, and clinical decision drivers across hospitals, diagnostic laboratories, clinics, and academic centers. These insights were cross-referenced with regulatory filings and product technical manuals to ensure alignment between claimed capabilities and operational realities. Analytical frameworks prioritized technology readiness, integration complexity, and supply chain dependencies to produce strategic recommendations that are practical and evidence-based. Transparency in assumptions and clear documentation of data sources underpin the credibility of the findings and support reproducibility for stakeholders seeking to validate specific elements locally.

Concluding synthesis emphasizing the intersection of technological innovation, operational resilience, and strategic alignment as prerequisites for durable success in diagnostics

The evolving influenza diagnostics environment presents both complexity and opportunity. Technological advances in molecular and rapid testing, combined with shifts toward decentralized care and heightened supply chain scrutiny, are redefining value drivers for clinical customers. At the same time, geopolitical and trade developments underscore the need for flexible sourcing and regional manufacturing strategies. For industry participants, success will depend on the ability to integrate technical innovation with operational excellence, to navigate regulatory expectations across jurisdictions, and to demonstrate tangible clinical impact through real-world validations.

Strategic clarity-rooted in an understanding of end-user workflows, regional infrastructure, and competitive positioning-enables organizations to prioritize investments that deliver differentiated value. Those that couple reliable supply with customer-focused service models, regulatory preparedness, and targeted partnerships will be positioned to lead in both stable and surge-demand environments. Ultimately, informed action based on rigorous evidence and close engagement with clinical stakeholders will determine who captures the most durable opportunities in the influenza diagnostics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Diagnostics Market, by Test Type / Product Type

  • 8.1. Rapid Influenza Diagnostic Tests (RIDTs)
  • 8.2. RT-PCR-Based Tests
  • 8.3. Isothermal Nucleic Acid Amplification Tests (NAATs) Immunofluorescence Assays (IFA) Serology Tests (ELISA, antibody detection) Digital / Connected Diagnostic Devices Multiplex Respiratory Panels (Flu A/B + RSV + COVID-19)
  • 8.4. Immunofluorescence Assays (IFA)
  • 8.5. Digital / Connected Diagnostic Devices
  • 8.6. Multiplex Respiratory Panels (Flu A/B + RSV + COVID-19)
  • 8.7. Home-Use / OTC Influenza Test Kits
  • 8.8. Serology Tests

9. Influenza Diagnostics Market, by Sample Type

  • 9.1. Nasopharyngeal swabs
  • 9.2. Throat swabs
  • 9.3. Bronchoalveolar lavage (BAL)
  • 9.4. Oropharyngeal swabs
  • 9.5. Blood/serum samples
  • 9.6. Nasal swabs

10. Influenza Diagnostics Market, by Technology

  • 10.1. Molecular Diagnostics
    • 10.1.1. Conventional PCR
    • 10.1.2. Isothermal Amplification
    • 10.1.3. Real Time PCR
      • 10.1.3.1. Multiplex PCR Kits
      • 10.1.3.2. Singleplex PCR Kits
  • 10.2. Immunodiagnostics
    • 10.2.1. Lateral flow assays
    • 10.2.2. Chemiluminescence assays
    • 10.2.3. Immunofluorescence
    • 10.2.4. ELISA

11. Influenza Diagnostics Market, by Mode of Testing / Setting

  • 11.1. Point-of-Care Testing (POCT)
  • 11.2. Laboratory Testing
  • 11.3. Home-Based Testing

12. Influenza Diagnostics Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Influenza Diagnostics Market, by Disease Application

  • 13.1. Seasonal Influenza Testing
  • 13.2. Travel Screening / Occupational Screening
  • 13.3. Pandemic/Novel Strain Detection
  • 13.4. Surveillance & Epidemiology

14. Influenza Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Influenza Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Influenza Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Influenza Diagnostics Market

18. China Influenza Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Becton, Dickinson and Company
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. BioMerieux S.A.
  • 19.9. Danaher Company
  • 19.10. F. Hoffmann-La Roche Ltd.
  • 19.11. GenMark Diagnostics, Inc.
  • 19.12. Hologic, Inc.
  • 19.13. Luminex Corporation
  • 19.14. Meridian Bioscience, Inc.
  • 19.15. OraSure Technologies, Inc.
  • 19.16. PerkinElmer, Inc.
  • 19.17. Quidel Corporation
  • 19.18. Siemens Healthineers
  • 19.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS (RIDTS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS (RIDTS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS (RIDTS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RT-PCR-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RT-PCR-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RT-PCR-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS (NAATS) IMMUNOFLUORESCENCE ASSAYS (IFA) SEROLOGY TESTS (ELISA, ANTIBODY DETECTION) DIGITAL / CONNECTED DIAGNOSTIC DEVICES MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS (NAATS) IMMUNOFLUORESCENCE ASSAYS (IFA) SEROLOGY TESTS (ELISA, ANTIBODY DETECTION) DIGITAL / CONNECTED DIAGNOSTIC DEVICES MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS (NAATS) IMMUNOFLUORESCENCE ASSAYS (IFA) SEROLOGY TESTS (ELISA, ANTIBODY DETECTION) DIGITAL / CONNECTED DIAGNOSTIC DEVICES MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAYS (IFA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAYS (IFA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAYS (IFA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIGITAL / CONNECTED DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIGITAL / CONNECTED DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIGITAL / CONNECTED DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX RESPIRATORY PANELS (FLU A/B + RSV + COVID-19), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-USE / OTC INFLUENZA TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-USE / OTC INFLUENZA TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-USE / OTC INFLUENZA TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY THROAT SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY THROAT SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY THROAT SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE (BAL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE (BAL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE (BAL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY OROPHARYNGEAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY OROPHARYNGEAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY OROPHARYNGEAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BLOOD/SERUM SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BLOOD/SERUM SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY BLOOD/SERUM SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NASAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING (POCT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING (POCT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING (POCT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOME-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEASONAL INFLUENZA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEASONAL INFLUENZA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEASONAL INFLUENZA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TRAVEL SCREENING / OCCUPATIONAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TRAVEL SCREENING / OCCUPATIONAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TRAVEL SCREENING / OCCUPATIONAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PANDEMIC/NOVEL STRAIN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PANDEMIC/NOVEL STRAIN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PANDEMIC/NOVEL STRAIN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SURVEILLANCE & EPIDEMIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SURVEILLANCE & EPIDEMIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SURVEILLANCE & EPIDEMIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 217. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 219. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 247. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 249. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 257. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 259. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE / PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE APPLICATION, 2018-2032 (USD MILLION)